Duavee FDA Approval History: What the Label and Safety Data Mean for You

What Duavee Is and Why the FDA Created a New Drug Category for It

Duavee is a fixed-dose combination of conjugated estrogens (CE) 0.45 mg and bazedoxifene (BZA) 20 mg in a single oral tablet taken once daily. The FDA approved it under a new mechanistic category called a tissue-selective estrogen complex, or TSEC. The idea is straightforward: estrogen relieves hot flashes, but in women who still have a uterus, estrogen alone raises the risk of endometrial hyperplasia and cancer. Traditionally, a progestogen was added to counteract that risk. Bazedoxifene, a selective estrogen receptor modulator (SERM), does that job instead.

Why a SERM Instead of a Progestogen?

Progestogens carry their own concerns, most notably a signal from the Women's Health Initiative showing that combined estrogen-progestogen therapy increased breast cancer risk compared with estrogen alone. Bazedoxifene acts as an estrogen antagonist in the uterus and breast while allowing estrogen to act on bone, brain thermostatic centers, and the vaginal epithelium. That tissue selectivity is the regulatory and clinical rationale for the TSEC category.

The European Regulatory Parallel

The European Medicines Agency approved the same combination under the brand name Viviant and later Duavive in Europe beginning in 2014, based on overlapping SMART trial data. The EMA review reinforced the FDA's conclusions on endometrial safety and vasomotor efficacy, and the EMA product information remains publicly available through the EMA's EPAR database for independent verification.

The Full FDA Approval Timeline

The regulatory path for Duavee took several years and two complete response cycles before the October 2013 green light.

NDA Submission and Early Review Challenges

Pfizer submitted New Drug Application (NDA) 022247 to the FDA's Division of Reproductive and Urologic Products (now the Division of Urology, Obstetrics and Gynecology). The agency issued a Complete Response Letter in 2011 requesting additional mammography and breast safety data. Pfizer responded with supplemental SMART-2 and SMART-3 mammographic density analyses, which showed that CE/BZA did not increase breast density, a finding that differentiated it from CE plus medroxyprogesterone acetate regimens.

October 3, 2013: Final Approval

On October 3, 2013, the FDA approved Duavee for two indications:

1. Moderate-to-severe vasomotor symptoms associated with menopause in women with a uterus.
2. Prevention of postmenopausal osteoporosis in women with a uterus (when estrogen is being used solely for prevention, non-estrogen medications should be considered first, per the label).

The osteoporosis prevention indication was later de-emphasized in prescribing guidance because the FDA's position is that osteoporosis prevention alone is not a sufficient reason to use a combined hormonal product when standalone bisphosphonates exist. The vasomotor symptoms indication remains the primary clinical use.

The SMART Trial Program: The Evidence Base

The key data package rests on five phase 3 randomized controlled trials called the Selective estrogens, Menopause, And Response to Therapy (SMART) trials. All trials enrolled postmenopausal women aged 40 to 75 years with an intact uterus.

SMART-1: Endometrial Safety at Two Years

SMART-1 was the longest and most clinically significant of the five trials. Published in 2009 in Menopause, it randomized 3,397 women to CE 0.45 mg / BZA 20 mg, CE 0.625 mg / BZA 20 mg, CE 0.45 mg / BZA 40 mg, or placebo for 24 months. The primary endpoint was endometrial hyperplasia at 12 months. The CE 0.45 / BZA 20 arm showed a 0% rate of hyperplasia at 12 months, meeting the FDA's pre-specified threshold of <1%.

SMART-2: Hot Flash Frequency and Severity

SMART-2, published in Menopause in 2013, enrolled 332 women and measured the change from baseline in the weekly frequency of moderate-to-severe hot flashes over 12 weeks. Women on CE 0.45 / BZA 20 experienced a mean reduction of 74% in weekly hot flash frequency compared with a 51% reduction in the placebo group. Severity scores fell by a statistically significant margin at weeks 4 and 12. This trial was the primary efficacy dataset the FDA reviewed for the vasomotor indication.

SMART-3, 4, and 5: Mammographic Density, Sleep, and Bone

SMART-3 examined breast endpoints. Mammographic density did not increase in the CE/BZA arms over 24 months, in contrast to CE plus medroxyprogesterone acetate. SMART-4 showed improvements in sleep disturbance scores. SMART-5 demonstrated bone mineral density preservation at the lumbar spine and total hip versus placebo at 24 months, which supported the osteoporosis prevention indication.

What the Current Duavee Label Says

The Duavee Prescribing Information is a class-level estrogen-progestogen label adapted for the CE/BZA combination. Here are the provisions most relevant to women reading this.

Black Box Warnings

The label carries four Black Box Warnings, all class-level:

1. Endometrial cancer. The addition of bazedoxifene is specifically intended to reduce this risk, and trial data showed rates below the 1% FDA threshold, but the class warning remains.
2. Cardiovascular disorders. The Women's Health Initiative found increased rates of stroke and deep vein thrombosis with oral estrogen-containing therapies.
3. Breast cancer. The label notes that CE/BZA has not been adequately studied in women with a personal history of breast cancer.
4. Probable dementia. The Women's Health Initiative Memory Study found increased rates of probable dementia in women aged 65 and older on combined hormone therapy; the label carries this warning though Duavee's own data in this age group are limited.

Dosage and Administration

The approved dose is one tablet (CE 0.45 mg / BZA 20 mg) once daily. The label specifies that the tablet should be swallowed whole and can be taken with or without food. No dose titration is included in the label. The prescribing information does not support cutting or crushing the tablet.

Contraindications on the Label

The label lists absolute contraindications:

• Undiagnosed abnormal uterine bleeding
• Known or suspected estrogen-dependent neoplasia
• Active or past venous thromboembolism
• Active or past arterial thromboembolic disease (stroke, myocardial infarction)
• Known liver impairment or disease
• Known protein C, protein S, or antithrombin deficiency or other thrombophilic disorders
• Pregnancy
• Known hypersensitivity to CE or BZA

Pregnancy, Lactation, and Contraception: The Non-Negotiable Facts

Duavee is contraindicated in pregnancy. This is not a relative contraindication or a risk-benefit discussion. The drug is indicated only for postmenopausal women, and estrogen-SERM combinations have not been studied in pregnant women. Animal data with bazedoxifene showed fetal harm. Under the FDA Pregnancy and Lactation Labeling Rule, the Duavee label states that exposure during pregnancy may cause fetal harm based on findings from animal reproduction studies, and the drug should be discontinued immediately if pregnancy occurs.

Lactation

Estrogen passes into breast milk and may reduce milk production. Bazedoxifene lactation transfer data in humans are not available. The label states that Duavee should not be used by women who are breastfeeding. The benefit-to-risk calculation here is clear: no approved indication exists for premenopausal lactating women, so there is no scenario in which the drug is appropriate during breastfeeding.

Contraception Note

Because Duavee is approved for postmenopausal women only, formal contraception requirements are not listed in the prescribing information. However, clinicians should confirm menopause status before prescribing. A woman who may still be perimenopausal and ovulating should not be prescribed this drug until menopause is confirmed (typically 12 consecutive months of amenorrhea, or via FSH and estradiol levels in ambiguous cases).

Who This Drug Is Right For, and Who It Is Not

Understanding the approved population matters because Duavee is sometimes asked about by women in earlier life stages.

Right For

• Postmenopausal women with a uterus who have moderate-to-severe hot flashes and want to avoid a progestogen
• Women who experienced progestogen-related side effects (mood changes, bloating, breast tenderness) on prior combined HRT regimens
• Women at baseline risk for osteoporosis who also need vasomotor symptom relief

Not Right For

• Perimenopausal women (not approved, and the hormonal environment is different)
• Women without a uterus (a standalone estrogen is simpler and carries less of a drug burden)
• Women with a personal or strong family history of estrogen receptor-positive breast cancer (inadequate safety data; discuss with an oncologist)
• Women with active or past VTE or arterial disease (absolute contraindication)
• Women currently pregnant or breastfeeding (absolutely contraindicated)
• Women with PCOS who are still cycling (not a menopausal drug; PCOS management in reproductive-age women requires entirely different approaches)

A practical framework for the prescribing conversation: ask three questions before Duavee comes up as an option. First, is menopause confirmed? Second, does the woman have a uterus? Third, is she free of the absolute contraindications listed above? Only if all three answers line up correctly does Duavee enter the differential. Clinicians at WomanRx use this three-gate check to standardize Duavee candidate selection across the telehealth platform.

Sex-Specific Pharmacokinetics: How Duavee Behaves in the Female Body

The pharmacokinetics of CE/BZA have been studied almost exclusively in postmenopausal women, which is appropriate given the indication but means extrapolation to other hormonal states is not possible.

Estrogen Metabolism and the Menopausal Liver

After oral administration, conjugated estrogens are hydrolyzed in the gastrointestinal tract and liver, converting to estrone and estradiol. In postmenopausal women, first-pass metabolism is significant. The FDA review documents note that steady-state estrone levels with CE 0.45 mg are substantially lower than those achieved with CE 0.625 mg alone, partly because bazedoxifene slightly alters the hepatic environment through SERM effects on sex hormone-binding globulin.

Bazedoxifene Pharmacokinetics

Bazedoxifene reaches peak plasma concentration in approximately 2.5 hours after oral dosing. Its half-life is around 30 hours, supporting once-daily dosing. It undergoes glucuronidation in the gut and liver. Bazedoxifene does not induce or inhibit CYP450 enzymes at clinical doses, which keeps the drug-drug interaction profile relatively clean. Renal impairment does not substantially alter bazedoxifene exposure, but the drug has not been formally studied in severe hepatic impairment, and liver disease is a contraindication.

Bone: Female-Specific Benefit

Postmenopausal bone loss accelerates sharply in the first three to five years after the final menstrual period, driven by estrogen withdrawal and its downstream effects on osteoclast activity. SMART-5 data showed that CE 0.45 / BZA 20 maintained lumbar spine BMD compared with placebo at 24 months, with a treatment difference of approximately 1.5% at the lumbar spine. Bazedoxifene alone (at 20 mg) has bone-protective properties demonstrated in the MORE and CORE trials for osteoporosis, so the TSEC combination produces additive skeletal benefit.

Post-Market Safety Surveillance Since 2013

FDA approval is not the end of the safety story. Post-market data matter, and Duavee has now been in clinical use for over a decade.

FDA Adverse Event Reporting System (FAERS) Data

The most commonly reported adverse events in the FAERS database for Duavee since 2013 include muscle spasms, nausea, diarrhea, dyspepsia, and abdominal pain on the gastrointestinal side. Thromboembolic events have been reported but at rates consistent with the class. No new safety signals have resulted in label changes through the most recent review period available on Drugs@FDA for NDA 022247.

Breast Safety Follow-Up

Breast cancer cases have been reported in post-market surveillance, as expected in any drug used by postmenopausal women at baseline risk. The Menopause Society's 2023 hormone therapy position statement notes that the breast safety profile of CE/BZA appears favorable compared with CE plus progestogen, citing the absence of mammographic density increases in the SMART trials, but acknowledges that long-term post-market breast incidence data are still accumulating.

The Society's statement also notes directly: "Available data suggest that the breast cancer risk with CE/BZA is lower than that with estrogen-progestogen therapy, but longer-term data are needed before definitive conclusions can be drawn." This is the evidence gap women deserve to hear plainly.

The Cardiovascular Picture Post-WHI

The Women's Health Initiative found a hazard ratio of 1.41 for stroke with CE 0.625 mg plus medroxyprogesterone acetate in women aged 50 to 79. Duavee uses a lower CE dose (0.45 mg), which may carry a lower absolute risk, but no head-to-head cardiovascular outcomes trial comparing CE 0.45 / BZA 20 to placebo has been completed with stroke or myocardial infarction as primary endpoints. The cardiovascular black box warning applies by class extrapolation, not from Duavee-specific outcomes data. Women with pre-existing cardiovascular risk factors should have that risk quantified before any oral estrogen-containing therapy is considered.

How Duavee Compares With Other Menopausal HRT Options

Postmenopausal women in the United States have several FDA-approved options for vasomotor symptoms.

| Option | Progestogen needed? | Uterus required for indication | Breast density effect | Route | |---|---|---|---|---| | CE/BZA (Duavee) | No | Yes | Neutral (SMART-3) | Oral | | CE + MPA (Prempro) | Already combined | Yes | Increases | Oral | | Estradiol alone | Yes, if uterus intact | No requirement | Variable | Oral, patch, gel, spray | | Fezolinetant (Veozah) | No | No requirement | No data (non-hormonal) | Oral |

Fezolinetant, approved by the FDA in May 2023 as the first neurokinin B antagonist for vasomotor symptoms, is the non-hormonal comparator for women who cannot or prefer not to use estrogen. Its mechanism targets the hypothalamic thermoregulation pathway directly, with no estrogen receptor activity.

The Evidence Gap in Women's Health: What We Still Do Not Know

Women have been historically underrepresented in cardiovascular and oncology outcomes trials. The SMART trials enrolled women with a mean age of 55 years, predominantly white, and healthy at baseline. Long-term cardiovascular outcomes in women over 65, in women with metabolic syndrome, or in women from diverse racial and ethnic backgrounds are not well characterized for CE/BZA specifically. The Menopause Society's 2023 position statement explicitly calls for better representation of Black, Hispanic, and Asian women in future menopause trial designs, since vasomotor symptom burden and cardiovascular risk differ across these groups.

This gap is a clinical reality you should know. If your demographic group was not well represented in the SMART trials, your clinician is partly extrapolating when applying those results to you.

Clinical Monitoring While on Duavee

The prescribing information and ACOG's guidance on menopausal hormone therapy recommend:

• Annual breast exam and mammogram per age-appropriate screening schedules
• Pelvic exam and endometrial assessment if any unexpected vaginal bleeding occurs (this warrants prompt evaluation regardless of the bazedoxifene component)
• Blood pressure monitoring at each visit, given the class-level cardiovascular concern
• Reassessment of the need to continue therapy at least annually, aiming to use the lowest effective dose for the shortest duration consistent with treatment goals

Reassessment does not mean automatic discontinuation at a set time point. The Menopause Society has moved away from the blanket "five-year rule" and toward individualized duration discussions based on the woman's symptom burden, risk profile, and informed preference.